Synergistic anti-inflammatory effect: simvastatin and pioglitazone reduce inflammatory markers of plasma and epicardial adipose tissue of coronary patients with metabolic syndrome

Diabetology & Metabolic Syndrome

Protásio Lemos da Luz²  Luís Alberto de Oliveira Dallan¹  Desidério Favarato¹  Maria de Lourdes Higuchi¹  Sérgio Ferreira de Oliveira¹  Adriana Ferreira Grosso¹ 

[1] Heart Institute (InCor) HCFMUSP, University of São Paulo Medical School, São Paulo, Brazil;Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da, Universidade de São Paulo, Av. Dr. Enéas de Carvalho Aguiar, 44, 5º andar, bloco II, sala 8 Cerqueira César, 05403-000 São Paulo, SP, Brazil

关键词: Simvastatin;    Pioglitazone;    Inflammation;    Epicardial adipose tissue;    Atherosclerosis;   

Others  :  803810
DOI  :  10.1186/1758-5996-6-47

 received in 2014-01-16, accepted in 2014-03-25,  发布年份 2014

【 摘 要 】

Background

The inappropriate secretion of adipocytokines plays a critical role in chronic inflammatory states associated with obesity-linked type 2 diabetes and atherosclerosis. The pleiotropic actions of simvastatin and pioglitazone on epicardial adipose tissue (EAT) are unknown. This study assessed the anti-inflammatory actions of simvastatin and pioglitazone on EAT in patients with coronary artery disease (CAD) and metabolic syndrome (MS).

Methods

A total of 73 patients with multivessel CAD who underwent elective bypass grafting were non-randomly allocated to one of four subgroups: Control (n = 17), simvastatin (20 mg/day, n = 20), pioglitazone (15 mg or 30 mg/day, n = 18), or simvastatin + pioglitazone (20 mg/day + 30 mg/day, respectively, n = 18); 20 valvar patients were also included. EAT samples were obtained during surgery. The infiltration of macrophages and lymphocytes and cytokines secretion were investigated using immunohistochemical staining and compared to plasma inflammatory biomarkers.

Results

Simvastatin significantly reduced plasma interleukin-6, leptin, resistin and monocyte chemoattractant protein-1 (p < 0.001 for all); pioglitazone reduced interleukin-6, tumoral necrose factor-alpha, resistin and matrix metalloproteinase-9 (p < 0.001 for all). Simvastatin + pioglitazone treatment further reduced plasmatic variables, including interleukin-6, tumoral necrose factor-alpha, resistin, asymmetric dimethylarginine and metalloproteinase-9 vs. the control group (p < 0.001). Higher plasma adiponectin and lower high sensitivity C-reactive protein concentrations were found simultaneously in the combined treatment group. A positive correlation between the mean percentage systemic and tissue cytokines was observed after treatments. T- and B-lymphocytes and macrophages clusters were observed in the fat fragments of patients treated with simvastatin for the first time.

Conclusions

Pioglitazone, simvastatin or combination treatment substantially reduced EAT and plasma inflammatory markers in CAD and MS patients. These tissue effects may contribute to the control of coronary atherosclerosis progression.

【 授权许可】

   
2014 Grosso et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Kershaw EE, Flier JS: Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004, 89:2548-2556.
• [2]Moreno PR, Murcia AM, Palacios IF, Leon MN, Bernardi VH, Fuster V, Fallon JT: Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 2000, 102:2180-2184.
• [3]Shoelson SE, Lee J, Goldfine AB: Inflammation and insulin resistance. J Clin Invest 2006, 116:1793-1801.
• [4]Haffner SM: The metabolic syndrome: inflammation, diabetes mellitus and cardiovascular disease. J Am Coll Cardiol 2006, 97:3A-11A.
• [5]Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, Arafat H, Sarov-Blat L, O’Brien S, Keiper EA, Johnson AG, Martin J, Goldstein BJ, Shi Y: Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 2003, 108:2460-2466.
• [6]Baker AR, Silva NF, Quinn DW, Harte AL, Pagano D, Bonser RS, Kumar S, McTernan PG: Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease. Cardiovasc Diabetol 2006, 5:1-7.
• [7]Permana PA, Menge C, Reaven PD: Macrophage-secreted factors induce adipocyte inflammation and insulin resistence. Biochem Biophys Res Commun 2006, 341:507-514.
• [8]Hirata Y, Kurobe H, Akaike M, Chikugo F, Hori T, Bando Y, Nishio C, Higashida M, Nakaya Y, Kitagawa T, Sata M: Enhanced inflammation in epicardial fat in patients with coronary artery disease. Int Heart J 2011, 52:139-142.
• [9]Hug C, Lodish HF: The role of the adipocyte hormone adiponectin in cardiovascular disease. Curr Opin Pharmacol 2005, 5:129-134.
• [10]Iacobellis G, Pistilli D, Gucciardo M, Leonetti F, Miraldi F, Brancaccio G, Gallo P, di Gioia CR: Adiponectin expression in human epicardial adipose tissue in vivo is lower in patients with coronary artery disease. Cytokine 2005, 29:251-255.
• [11]Zhou A, Murillo H, Peng Q: Impact of partial volume effects on visceral adipose tissue quantification using MRI. J Magn Reson Imaging 2011, 34:1452-1457.
• [12]Montani JP, Carroll JF, Dwyer TM, Antic V, Yang Z, Dulloo AG: Ectopic fat storage in heart, blood vessels and kidneys in the pathogenesis of cardiovascular diseases. Int J Obes Relat Metab Disord 2004, 28:S58-S65.
• [13]Iacobellis G, Assael F, Ribaudo MC, Zappaterreno A, Alessi G, Di Mario U, Leonetti F: Epicardial fat from echocardiography: a new method for visceral adipose tissue prediction. Obes Res 2003, 11:304-310.
• [14]Iacobellis G, Ribaudo MC, Assael F, Vecci E, Tiberti C, Zappaterreno A, Di Mario U, Leonetti F: Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk. J Clin Endocrinol Metab 2003, 88:5163-5168.
• [15]Luz PL, Nishiyama M, Chagas AC: Drugs and lifestyle for the treatmen and prevention of coronary artery disease – comparative analysis of the scientific basis. Braz J Med Biol Res 2011, 44:973-991.
• [16]Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA: Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2004, 89:4312-4319.
• [17]Khan M, Murray FT, Karunaratne M, Perez A: Pioglitazone and reductions in post-challenge glucose levels in patients with type 2 diabetes. Diabetes Obes Metab 2006, 8:31-38.
• [18]Permana PA, Zhang W, Wabitsch M, Fischer-Posovszky P, Duckworth WC, Reaven PD: Pioglitazone reduces inflammatory responses of human adipocytes to factors secreted by monocytes/macrophages. Am J Physiol Endocrinol Metab 2009, 296:E1076-E1084.
• [19]Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ, National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239.
• [20]Hanley AJ, Karter AJ, Williams K, Festa A, D’Agostino RB Jr, Wagenknecht LE, Haffner SM: Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the insulin resistance atherosclerosis study. Circulation 2005, 112:3713-3721.
• [21]Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S: Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001, 103:1933-1935.
• [22]Hanefeld M, Marx N, Pfützner A, Baurecht W, Lübben G, Karagiannis E, Stier U, Forst T: Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity c-reactive protein: the PIOSTAT study. J Am Coll Cardiol 2007, 49:290-297.
• [23]Forst T, Karagiannis E, Lübben G, Hohberg C, Schöndorf T, Dikta G, Drexler M, Morcos M, Dänschel W, Borchert M, Pfützner A: Pleiotrophic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease. Atherosclerosis 2008, 197:311-317.
• [24]Pfützner A, Marx N, Lübben G, Langenfeld M, Walcher D, Konrad T, Forst T: Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 2005, 45:1925-1931.
• [25]Walcher D, Marx N: Insulin resistance and cardiovascular disease: the role of PPARγ activators beyond their anti-diabetic action. Diab Vasc Dis Res 2004, 1:76-81.
• [26]Suganami T, Ogawa Y: Adipose tissue macrophages: their role in adipose tissue remodeling. J Leukoc Biol 2010, 88:33-39.
• [27]Sacks HS, Fain JN, Cheema P, Bahouth SW, Garrett E, Wolf RY, Wolford D, Samaha J: Inflammatory genes in epicardial fat contiguous with coronary atherosclerosis in the metabolic syndrome and type 2 diabetes: changes associated with pioglitazone. Diabetes Care 2011, 34:730-733.
• [28]Phillips SA, Ciaraldi TP, Oh DK, Savu MK, Henry RR: Adiponectin secretion and response to pioglitazone is depot dependent in cutured human adipose tissue. Am J Physiol Endocrinol Metab 2008, 295:E842-E850.
• [29]Fain JN, Cowan GS Jr, Buffington C, Andersen RN, Pouncey L, Bahouth SW: Regulation of leptin release by troglitazone in human adipose tissue. Metabolism 2000, 49:1485-1490.
• [30]Rasouli N, Yao-Borengasser A, Miles LM, Elbein SC, Kern PA: Increase plasma adiponectin in response to pioglitazone does not result from increased gene expression. Am J Physiol Endocrinol Metab 2006, 290:E42-E46.
• [31]Iacobelis G, Corradi D, Sharma AM: Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart. Nature 2005, 2:536-543.
• [32]Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, Okamoto Y, Ohashi K, Nagaretani H, Kishida K, Nishizawa H, Maeda N, Kobayashi H, Hiraoka H, Matsuzawa Y: Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003, 107:671-674.
• [33]Teijeira-Fernandez E, Eiras S, Shamagian LG: Epicardial adipose tissue adiponectin in patients with metabolic syndrome. Cytokine 2011, 54:185-190.
• [34]Iacobellis G, di Gioia CR, Cotesta D, Petramala L, Travaglini C, De Santis V, Vitale D, Tritapepe L, Letizia C: Epicardial adipose tissue adiponectin expression is related to intracoronary adiponectin levels. Horm Metab Res 2009, 41(3):227-231.
• [35]Iacobellis G, Cotesta D, Petramala L, De Santis V, Vitale D, Tritapepe L, Letizia C: Intracoronary adiponectin levels rapidly and significantly increase after coronary revascularization. Int J Cardiol 2010, 144(1):160-163.
• [36]Meier D, Bornmann C, Chappaz S, Schmutz S, Otten LA, Ceredig R, Acha-Orbea H, Finke D: Ectopic lymphoid-organ development occurs through interleukin 7-mediated enhanced survival of lymphoid-tissue-inducer cells. Immunity 2007, 26:643-654.
• [37]Lötzer K, Döpping S, Connert S, Gräbner R, Spanbroek R, Lemser B, Beer M, Hildner M, Hehlgans T, van der Wall M, Mebius RE, Lovas A, Randolph GJ, Weih F, Habenicht AJ: Mouse aorta smooth muscle cells differentiate into lymphoid tissue organizer-like cells on combined tumor necrosis factor receptor-1/lymphotoxin beta-receptor NF-kappaB signaling. Arterioscler Thromb Vasc Biol 2010, 30:395-402.
• [38]Drayton DL, Liao S, Mounzer RH, Ruddle NH: Lymphoid organ development: from ontogeny to neogenesis. Nat Immunol 2006, 7:344-353.